RE:RE:RE:RE:RE:RE:IBD News - Q3?So am I Harper ... and I agree with you (in general).
But we're not making widgets here. We're dealing with the unknown in drug development - as we learned back in the AME.
So if you were to ask me for a schedule in drug development, I'd tell you that you're not getting one.
That's not acceptable either.
So you're stuck getting what you get.
------------------
Example:
If it doesn't come up in your animal/rodent studies but you only see it in human's - that creates a problem when your shareholders want timelines. Remember - you can't test in humans until you're given the OK. Then it's a whole new ballgame (as we are finding out with H2S and the liver's saturated response).
This is not a typical liver problem yet some would like you to think that. Why? Because they don't know better.
It doesn't help if you are partially blind to the complexities of H2S but yet you're expected to navigate that maze with perfection - not going to happen.
Finally, we are talking about events at the cell level and we are limited to the tools that exist at that level. Brings us back to the partially blinded aspect.
That's just the beginning. The more you learn and the further you travel down this rabbit's hole - you gain a whole new appreciation to how we even got to this point.
------------
Some call it failure but I see it differently ... this is the natural progression in H2S drug development with limited cash available ... and ... a beautiful pivot at the right time (from chronic to acute). P2 will either prove that pivot to be well executed or a failure.
But back to the question you asked ... why not stay on track? If I gave you a gun and a map and dropped you on a beach somewhere and I said to you, here are a few possible locations of the prisoner. By the way, your government needs to know when you will find the prisoner. What would you answer?
Remember ...
Devise the plan...communicate the plan...execute to plan.
How would you commit to this old fashion approach?
So hard when you don't know what barriers are going to get in the way.
So hard when you don't have enough information.
So hard when you're not even sure what resources you're going to need - or be able to find.
And in drug development - safety first - that's a huge barrier in moving a schedule forward.
That's what H2S is all about.
So much to learn.
I'm guessing we're going to need to earmark about $50MM to $100MM in pure H2S science (one day) - if we can even get/develop the right measurement tools.
Can we get there ? Here's to hoping that OTENA can open those doors to more and more drug development.